Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma

Journal of Pediatric Surgery

Volumn 47, Issue 6, 2012, Pages 1223-1227

  Barlow, Meade ^a,b   Edelman, Morris ^a   Glick, Richard D ^a   Steinberg, Bettie M ^a,b   Soffer, Samuel Z ^a,b  

^a Northwell Health   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Celecoxib; Cyclooxygenase 2; Invasion assay; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; ROFECOXIB;

BASEMENT MEMBRANE; CANCER INVASION; CELL COUNT; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; EWING SARCOMA; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; SARCOMA CELL; CANCER CELL; DRUG MECHANISM; IN VITRO STUDY;

BASEMENT MEMBRANE; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTONES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PYRAZOLES; SARCOMA, EWING; SULFONAMIDES; SULFONES;

EID: 84862489775     PISSN: 00223468     EISSN: 15315037     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2012.03.031     Document Type: Conference Paper

References (25)

1. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-9. (Pubitemid 24236016)
2. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275-81. (Pubitemid 28186797)
3. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887-93. (Pubitemid 20307920)
4. Pinkerton CR, Bataillard A, Guillo S, et al. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 2001;37:1338-44. (Pubitemid 32588743)
5. Ruegg C, Zaric J, Stupp R. Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Ann Med 2003;35:476-87. (Pubitemid 37421559)
6. Gendy AS, Lipskar A, Glick RD, et al. Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. J Pediatr Surg 2011;46:108-14.
7. Lipskar AM, Glick RD, Huang J, et al. Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma. J Pediatr Surg 2009;44:1139-46 [discussion 46-7].
8. Cervello M, Bachvarov D, Cusimano A, et al. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. Omics 2011;15:383-92.
9. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemo-prevention. Biochem Pharmacol 2004;68:1089-100.
10. Fatima N, Yi M, Ajaz S, et al. Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. Cancer Epidemiol Biomarkers Prev 2008;17:3051-61.
11. Gee J, Lee IL, Jendiroba D, et al. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 2006;15:471-7.
12. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840-55. (Pubitemid 46179475)
13. Roche-Nagle G, Connolly EM, Eng M, et al. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer 2004;91:359-65. (Pubitemid 39037084)
14. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21. (Pubitemid 33741877)
15. Brown WA, Skinner SA, Vogiagis D, et al. Inhibition of beta-catenin translocation in rodent colorectal tumors: a novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer. Dig Dis Sci 2001;46:2314-21. (Pubitemid 33042326)
16. Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2) - independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-47. (Pubitemid 43983297)
17. Dihlmann S, von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005;113:515-24. (Pubitemid 40038726)
18. Maier TJ, Janssen A, Schmidt R, et al. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005;19:1353-5. (Pubitemid 41113747)
19. Chan A, Akhtar M, Brenner M, et al. The GTPase Rac regulates the proliferation and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. Mol Med 2007;13:297-304. (Pubitemid 47175039)
20. Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 2001;15:1622-4.
21. Prasit P, Wang Z, Brideau C, et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999;9:1773-8.
22. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-66. (Pubitemid 32112486)
23. Tomozawa S, Nagawa H, Tsuno N, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999;81:1274-9.
24. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83: 324-8. (Pubitemid 30453571)
25. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66. (Pubitemid 34196319)